24/7 Market News Snapshot 13 January, 2025 – Phio Pharmaceuticals Corp. Common Stock (NASDAQ:PHIO)

January 13, 2025

DENVER, Colo., 13 January, 2025 (247marketnews.com) – (NASDAQ:PHIO) are discussed in this article.
Phio Pharmaceuticals Corp. has recently experienced a significant surge in investor interest, with its stock soaring to $2.917 in pre-market trading, reflecting an impressive 72.60% increase from the previous close of $1.690. This surge, characterized by a trading volume of 2.82 million shares, highlights the heightened enthusiasm surrounding the company’s novel therapies. Analysts are optimistic, suggesting that this momentum may indicate strong market validation of Phio’s promising pipeline, making it a key stock to monitor as market dynamics evolve throughout the day.

Concurrently, Phio Pharmaceuticals announced encouraging preliminary results from its ongoing Phase 1b clinical study of PH-762, aimed at enhancing immune responses against cancer. The study, which assesses the safety and tolerability of the INTASYL® siRNA gene silencing technology, revealed remarkable outcomes in the second cohort. Notably, two patients achieved a complete response, indicating total tumor clearance for cutaneous squamous cell carcinoma (cSCC), while a third patient showed a 90% reduction in tumor size with partial response, and another exhibited stable disease.

Mary Spellman, M.D., acting Chief Medical Officer, expressed her enthusiasm about the findings, noting the profound tumor responses alongside reassuring safety data. The absence of significant treatment-emergent adverse effects supports the well-tolerated nature of the intratumoral injections delivered during the trial. Robert Bitterman, CEO of Phio Pharmaceuticals, emphasized the promise of these early-stage results, aligning with the company’s commitment to pursuing innovative cancer therapies.

Phio Pharmaceuticals continues to leverage its unique INTASYL technology as it advances through the clinical study phase, demonstrating its dedication to transforming therapeutic approaches for patients facing cancer challenges. The company plans to further evaluate higher dose concentrations of PH-762 as part of its ongoing efforts to deliver impactful treatment options in the oncology space.

Related news for (PHIO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.